December 8, 2025Blood

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

View Full Paper

Ask AI

Bookmark

Authors

CRChristian RécherCentre Hospitalier Universitaire de Toulouse TLThibaut LeguayUniversité de Bordeaux MCMartin CarréCentre Hospitalier Universitaire de Grenoble

Discussion

Member takes

Implication

Randomized trial examines relapse-free survival and treatment tolerability in younger adults with newly diagnosed AML, indicating dexamethasone improves tolerability without affecting RFS.

Key Points

Adding dexamethasone to high-dose cytarabine resulted in improved tolerability without enhancing relapse-free survival.
For 220 patients followed for median 49.3 months, 5-year relapse-free survival was 46% for high-dose cytarabine alone.
Randomized trial assessed effects on primary endpoint of relapse-free survival in younger adults with AML post-remission.
The findings suggest further exploration of inflammatory markers in AML treatment could be beneficial.

Cite This Study

Récher et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d971 https://doi.org/10.1182/blood-2025-881

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial examines relapse-free survival and treatment tolerability in younger adults with newly diagnosed AML, indicating dexamethasone improves tolerability without affecting RFS.

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Discussion

Member takes

Implication

Key Points

Cite This Study

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider